Centro Ricerche Oncologiche Mercogliano - CROM

Under Construction

CROM is acronym of Oncology Research Center of Mercogliano; the establishment and management of the Center is entrusted to  the National Cancer Institute of Naples (INT)- Fondazione G. Pascale, according to the Resolution n. 1630 of Campania Regional Council and to the Convention among the Institute, Campania Government and Avellino Provincial Council.
It  has its offices at the building ex-IPAI (Abandoned Children Institute),it belongs to the Avellino Provincial  Council and it has been given Malzoni family; it is dedicated to Doctor Fiorentino Lo Vuolo, famous personality in the Public Health Service. The Avellino Provincial Council provided to the aseismic updating of the building and it has done the structure to the National Cancer Institute of Naples.
The Center is dedicated to Dr. Fiorentino Lo Vuolo, famous personality in the Public Health Service.
In order to develop and to carry out research, service and training programs, CROM, through a local planning, offers oneself as a connecting system that establishes collaborations and synergies with the others public and private research centers, heath care and the Universities

CROM carries out activities of:

• research, typically in pre-clinical oncology molecular pharmacology
• training and diffusion of knowledge
• innovation and technological transfer

Research

1. Molecular characterization of neoplasms and development of innovative therapeutic strategies (Project Leader: Nicola Normanno).
2. Chronic inflammation and cancer: holistic approach to the cancer through a study of immunoregulatory, cellular and humoral networks, and dynamics of complex biological systems (Project Leader: Giuseppe Castello).
3. Cell cycle and cancer: from molecular oncology to translational therapy (Project Leader: Antonio Giordano).
4. Study of resistance mechanisms to anticancer drugs using approaches based on 2D-DIGE proteomic platform coupled to Mass Spectometry (Project Leader: Alfredo Budillon).
5. Preclinical and clinical development of new PET radiopharmaceuticals for agonists and antagonists peptides of somatostatin receptors marked F-18 (Project Leader: second Lastoria).

Labs

• BioImaging
• RadioPharmaceutical facility
• RadioPharmacy
• Histopathological & image Analysis
• Biochemistry and Lead Generation
• Pharmacogenetics and Metabolomics
• Molecular Immunology & Immunomomitoring
• Pharmacology & Proteomics
• Cell Biology and stem Cell
• Toxicology
• High-throughput screening (HTS)
• Pharmacogenomics
• Drug Design- System Biology
• Animal facility